doi:10.2174/18715273113126660137 110
Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)
Methylcobalamin is contraindicated in patients with methylcobalamin hypersensitivity or hypersensitivity to any of the medication components
At the firm, Beth advises individuals and organizations navigating complex state and federal laws that govern transactions, compliance, and reimbursement
*Louisiana Even with the number of GLP-1 prescriptions dropping nearly 12% in 2024, that still leaves about 20% of the population with a GLP-1
zero events in both the treatment and placebo group in all trials)